Nuformix PLC Appointment of Chief Executive Officer (6767H)
07 Diciembre 2020 - 1:00AM
UK Regulatory
TIDMNFX
RNS Number : 6767H
Nuformix PLC
07 December 2020
Nuformix plc
Appointment of Chief Executive Officer
Dr Anne Brindley to start with immediate effect
Cambridge, UK - 7 December 2020: Nuformix plc (LSE:NFX;
"Nuformix", the "Company" or the "Group"), a drug re-purposing
specialist, is pleased to announce the appointment of Dr Anne
Brindley as Chief Executive Officer "CEO" and Executive Director of
the Company with immediate effect.
Anne has over 30 years' experience in Big Pharma, Biotech and
smaller R&D companies, with a proven international track record
of leading organisations through strategic change and driving
projects and portfolios through discovery and development to
market.
Anne was previously CEO of Advent Pharmaceuticals Pty Ltd,
Melbourne, Australia, a specialty R&D company focused on
generic inhaled products for global markets. In that role, Anne led
a successful sale of the products and assets to AuroScience Pty
Ltd, Melbourne, Australia, a wholly owned subsidiary of Aurobindo
Pharma USA Inc. She subsequently became CEO of AuroScience Pty
Ltd.
Before moving to Advent, Anne was a Board member and Managing
Director of Respivert Ltd, a subsidiary of Janssen Pharmaceuticals
(part of Johnson & Johnson, Inc), where she was responsible for
leadership and operations of the company, including discovery /
development programmes spanning three novel classes of drug for
idiopathic pulmonary fibrosis, chronic obstructive pulmonary
disease and asthma, as well as out-licensing activities. Prior to
this, Anne occupied the role of Vice President and Head of
Inhalation Products.
Anne's earlier career included roles as Executive Vice
President, Pharmaceutical Development & Project Management at
Skyepharma plc, a specialty pharma company developing innovative
oral and inhalation products, and senior positions in Product
Development at AstraZeneca PLC. Prior to this, Anne worked at
GlaxoSmithKline plc.
Dr Chris Blackwell, Non-Executive Chairman, commented:
" I am delighted to welcome Anne as the CEO of Nuformix. Anne
has extensive expertise in small molecule R&D spanning
discovery, early and late stage development, through to
registration and commercialisation in respiratory and oncology
therapy areas for both innovator and generic products. She is a
renowned expert in inhaled products and drug/device combinations.
This wealth of relevant experience coupled with her leadership and
Board experience will help the Company move forward with its
strategic priorities. I now look forward to working with Anne and
the rest of the Board as I resume the role of Non-Executive
Chairman."
Commenting on her appointment, Dr Anne Brindley said:
"I am delighted to have accepted the role of CEO of Nuformix at
this important time for the Company. I look forward to driving the
business strategy and achieving the Company's objectives. Having
worked in the pharma industry for over 30 years, I can see that
Nuformix has assets and technology that have great potential and I
intend to work with the Board to take these forward in
development."
No further information is required to be disclosed pursuant to
LR 9.6.13R of the UK Listing Rules.
The person responsible for arranging the release of this
announcement on behalf of the Company is Dr Chris Blackwell,
Non-Executive Chairman.
Enquiries:
Nuformix plc
Anne Brindley, CEO
Fleur Wood, Investor Relations
Email: fleur.wood@nuformix.com +44 (0)1223 627222
Novum Securities Limited
Jon Belliss / Colin Rowbury +44 (0)20 7399 9427
About Nuformix
Nuformix is a pharmaceutical development company focused on
unlocking the therapeutic potential and value of known drugs to
develop new novel medicines which provide therapeutic and
commercial advantages to the currently available drug form.
Nuformix's model of repurposing drugs utilises many technologies
but is focussed on its acknowledged expertise in the use of
cocrystal technology through which the Group has developed and
patented novel forms of small molecules. Its platform is not
therapy-specific but instead has broad application across a wide
range of indications. Using its technology, the Group is developing
proprietary medicines for its own development pipeline and in
partnership with pharmaceutical and biotech companies.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX. For more information please
visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOATFBATMTAMBLM
(END) Dow Jones Newswires
December 07, 2020 02:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De May 2023 a May 2024